Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.

Naga ChalasaniManal F AbdelmalekRohit LoombaKris V KowdleyArthur J McCulloughSrinivasan DasarathyBrent A Neuschwander-TetriNorah TerraultBeatrice FergusonReshma ShringarpureDavid ShapiroArun J Sanyal

Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)

Readily available non-invasive markers may predict improvement in liver fibrosis in patients with NASH. Upon external confirmation and further refinement in larger populations, these markers may serve as surrogate endpoints in NASH clinical trials.

Keyphrases

liver fibrosis
clinical trial
liver injury
randomized controlled trial
phase ii
open label
study protocol
drug induced